Literature DB >> 22263011

Long-term follow up of patients affected by pulmonary carcinoid at the Istituto Nazionale Tumori of Milan: a retrospective analysis.

S Pusceddu1, L Catena, M Valente, R Buzzoni, B Formisano, M Del Vecchio, M Ducceschi, L Tavecchio, A Fabbri, E Bajetta.   

Abstract

Neuroendocrine tumors of the lung involve an heterogeneous group of tumors representing a wide range of histological variants, from well-differentiated typical carcinoid (TC) tumors to poorly differentiated small cell carcinomas. The epidemiology, clinical outcome, and management of these neoplasms differ significantly from other lung malignancies. The main aim of this report consists in describing the single Center experience of the Istituto Nazionale Tumori of Milan on neuroendocrine lung tumors, with an emphasis on bronchopulmonary carcinoid subtypes. From 1986 to 2009, 91 cases of carcinoid tumors were diagnosed; these were divided in two series, according to typical (66 patients) or atypical [25] histotypes. These two groups were compared in relation to various features, including pathologic classification, clinical behavior, treatment modalities and long-term survival. At the moment of diagnosis 11 patients had locally advanced/metastatic disease, while 80 patients showed non metastatic disease. The comparative analysis between typical and atypical series disclosed significant differences in terms of long-term survival; in fact, 5-year and 10-year survival rates were 98 % and 94 % for the first carcinoid series versus 76 % and 18 % for the atypical series, respectively (p<0.001). The median overall survival (OS) was 76 months (range 3-182) for atypical carcinoids and has not yet been reached for TCs patients.

Entities:  

Keywords:  carcinoid; lung cancer; neuroendocrine; pulmonary

Year:  2010        PMID: 22263011      PMCID: PMC3256433     

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  21 in total

1.  Bronchial carcinoid tumors: surgical management and long-term outcome.

Authors:  Pier Luigi Filosso; Ottavio Rena; Giovanni Donati; Caterina Casadio; Enrico Ruffini; Esther Papalia; Alberto Oliaro; Giuliano Maggi
Journal:  J Thorac Cardiovasc Surg       Date:  2002-02       Impact factor: 5.209

Review 2.  Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature.

Authors:  G Fink; T Krelbaum; A Yellin; D Bendayan; M Saute; M Glazer; M R Kramer
Journal:  Chest       Date:  2001-06       Impact factor: 9.410

3.  Experience in treatment of metastatic pulmonary carcinoid tumors.

Authors:  D Granberg; B Eriksson; E Wilander; P Grimfjärd; M L Fjällskog; K Oberg; B Skogseid
Journal:  Ann Oncol       Date:  2001-10       Impact factor: 32.976

4.  Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients.

Authors:  Giuseppe Pelosi; Jaime Rodriguez; Giuseppe Viale; Juan Rosai
Journal:  Am J Surg Pathol       Date:  2005-02       Impact factor: 6.394

5.  Daily cyclic changes in the urinary excretion of 5-hydroxyindoleacetic acid in patients with carcinoid tumors.

Authors:  Johanna M Zuetenhorst; Catharina M Korse; Johannes M G Bonfrer; Ellen Peter; Cornelis B H W Lamers; Babs G Taal
Journal:  Clin Chem       Date:  2004-07-09       Impact factor: 8.327

6.  Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid.

Authors:  W D Travis; W Rush; D B Flieder; R Falk; M V Fleming; A A Gal; M N Koss
Journal:  Am J Surg Pathol       Date:  1998-08       Impact factor: 6.394

7.  Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours.

Authors:  E Bajetta; L Ferrari; G Procopio; L Catena; E Ferrario; A Martinetti; M Di Bartolomeo; R Buzzoni; L Celio; M Vitali; E Beretta; E Seregni; E Bombardieri
Journal:  Ann Oncol       Date:  2002-04       Impact factor: 32.976

8.  Pulmonary carcinoid tumours: indolent but not benign.

Authors:  Sara De Dosso; Emilio Bajetta; Giuseppe Procopio; Diego Cortinovis; Roberto Buzzoni; Laura Catena; Marco Platania; Elena Verzoni
Journal:  Oncology       Date:  2008-04-16       Impact factor: 2.935

9.  [Trends in prognostic factors for neuroendocrine lung tumors].

Authors:  Mariano García-Yuste; Laureano Molins; José M Matilla; Federico González-Aragoneses; Javier López-Pujol; Guillermo Ramos; Mercedes de la Torre
Journal:  Arch Bronconeumol       Date:  2007-10       Impact factor: 4.872

10.  5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors.

Authors:  E Bajetta; L Rimassa; C Carnaghi; E Seregni; L Ferrari; M Di Bartolomeo; E Regalia; A Cassata; G Procopio; L Mariani
Journal:  Cancer       Date:  1998-07-15       Impact factor: 6.860

View more
  3 in total

1.  A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors.

Authors:  Marta Peri; Edoardo Botteri; Eleonora Pisa; Filippo De Marinis; Antonio Ungaro; Francesca Spada; Chiara Maria Grana; Roberto Gasparri; Lorenzo Spaggiari; Nicole Romentz; Giuseppe Badalamenti; Antonio Russo; Nicola Fazio
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

2.  Combination of carbonic anhydrase inhibitor, acetazolamide, and sulforaphane, reduces the viability and growth of bronchial carcinoid cell lines.

Authors:  Reza Bayat Mokhtari; Sushil Kumar; Syed S Islam; Mehrdad Yazdanpanah; Khosrow Adeli; Ernest Cutz; Herman Yeger
Journal:  BMC Cancer       Date:  2013-08-08       Impact factor: 4.430

Review 3.  Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas.

Authors:  Bryan Oronsky; Patrick C Ma; Daniel Morgensztern; Corey A Carter
Journal:  Neoplasia       Date:  2017-11-05       Impact factor: 5.715

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.